Companies · Biotechnology

ZS Genetics Inc

Wakefield · Biotechnology

Diligence memoA one-page analyst read on ZS Genetics Inc — recommendation, valuation, rhythm, risks.
$2.9M
Total raised · real
5
Rounds
1.7×
Latest step-up
Top 68%
Sector rank · raised
Seed
Latest stage · inferred · Mon Apr 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

ZS Genetics Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.11× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era.
Dormant
  • Last raise 11.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

ZS Genetics Inc is one of 4291 Biotechnology companies tracked from Wakefield. By capital raised it ranks in the long tail (ahead of 33% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2010-05-03 Raised $1.7M (real) Modeled valuation $77M (est)$1.7M$77MSeed2010Pre-Seed · 2010-05-03 Raised $620K (real) Modeled valuation $34M (est)$620K$34MPre-Seed2010Pre-Seed · 2010-05-03 Raised $303K (real) Modeled valuation $17M (est)$303K$17MPre-Seed2010Pre-Seed · 2010-05-03 Raised $620K (real) Modeled valuation $34M (est)$620K$34MPre-Seed2010Seed · 2014-05-05 Raised $100K (real) Modeled valuation $4.4M (est)$100K$4.4MSeed2014Seed · 2015-04-27 Raised $170K (real) Modeled valuation $7.5M (est)$170K$7.5MSeed2015+$620K+$303K+$620K+$100K+$170KCumulative $3.5M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.7M · 2010
Bridge · Seed-stage$620K · 2010smaller follow-on
Bridge · Seed-stage$303K · 2010smaller follow-on
Bridge · Seed-stage$620K · 2010smaller follow-on
Seed extension$100K · 2014
Seed extension$170K · 2015

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$7.5M
Base estimate est.
$122K
Conservative case
$59.2M
Upside case
$850K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $76.6M · 2010-05-032010Pre-Seed · modeled $34.2M · 2010-05-03Pre-Seed · modeled $16.7M · 2010-05-03Pre-Seed · modeled $34.2M · 2010-05-03Seed · modeled $4.4M · 2014-05-05Seed · modeled $7.5M · 2015-04-272015
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
11.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$586K/yr
Capital velocity
16.2 yr
On record since
2010
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.4× of median
This company$2.9M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.1× of median
This company$170K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$7.5M
Sector median$64.2M

Raised more than 33% of sector peers (real $). Modeled value above 15% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #118 of 122.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Harpoon Medical, Inc. · Seed Raised $7.8M · modeled $173.2M (est)Admittance Technologies, Inc. · Seed Raised $3.9M · modeled $173.0M (est)Bell Biosystems, Inc. · Seed Raised $6.2M · modeled $169.2M (est)Nexstim Plc · Seed Raised $3.7M · modeled $166.4M (est)Iontera, Inc. · Seed Raised $16.8M · modeled $164.2M (est)Monteris Medical Inc · Seed Raised $9.0M · modeled $163.1M (est)Abzena plc · Seed Raised $4.3M · modeled $160.0M (est)Alkahest, Inc. · Seed Raised $3.5M · modeled $155.4M (est)ONCoPEP, Inc. · Seed Raised $12.7M · modeled $153.5M (est)Cal-X Stars Business Accelerator, Inc. · Seed Raised $3.4M · modeled $151.4M (est)QT Holdings Corp. · Seed Raised $3.8M · modeled $145.9M (est)Insight Genetics, Inc. · Seed Raised $5.5M · modeled $135.4M (est)ZS Genetics Inc (this company) Raised $2.9M · modeled $7.5M (est)ZS Genetics Inc
CompanyStageRaised · realValue · estvs peer med.
Harpoon Medical, Inc.Seed$7.8M$173.2M2.59×
Admittance Technologies, Inc.Seed$3.9M$173.0M2.59×
Bell Biosystems, Inc.Seed$6.2M$169.2M2.53×
Nexstim PlcSeed$3.7M$166.4M2.49×
Iontera, Inc.Seed$16.8M$164.2M2.46×
Monteris Medical IncSeed$9.0M$163.1M2.44×
Abzena plcSeed$4.3M$160.0M2.40×
Alkahest, Inc.Seed$3.5M$155.4M2.33×
ONCoPEP, Inc.Seed$12.7M$153.5M2.30×
Cal-X Stars Business Accelerator, Inc.Seed$3.4M$151.4M2.27×
QT Holdings Corp.Seed$3.8M$145.9M2.19×
Insight Genetics, Inc.Seed$5.5M$135.4M2.03×
ZS Genetics Inc this companySeed$2.9M$7.5M0.11×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.7M2010-05-03$8.6M$76.6M90%
Pre-Seed$620K2010-05-03$3.4M$34.2M90%
Pre-Seed$303K2010-05-03$1.7M$16.7M90%
Pre-Seed$620K2010-05-03$3.4M$34.2M90%
Seed$100K2014-05-05$500K$4.4M90%
Seed$170K2015-04-27$850K$7.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.7M2010-05-03
    • First recorded raise — entered as Seed.
  2. Pre-Seed$620K2010-05-03
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.8× smaller than the prior — bridge or down round.
  3. Pre-Seed$303K2010-05-03
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× smaller than the prior — bridge or down round.
  4. Pre-Seed$620K2010-05-03
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× larger than the prior — scaling up.
  5. Seed$100K2014-05-05
    • Raised again after 48 mo — slower than the ~14 mo sector norm.
    • Round 6.2× smaller than the prior — bridge or down round.
  6. Seed$170K2015-04-27
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
Intelligence
2016 ~Q2
Modeled next raise · ~12mo cadence
$289K
Modeled next size est.range $188K$462K
1.7×
Last step-up
$586K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Thomas D. Abert2 other2010-05
Jane E. Hager1 other2010-05
Thomas A Shields1 other2010-05
Bill W Ward2010-05
Frank E. Ferguson2010-05
John A McCarthy2015-04
William R Glover2010-05
Registry & provenance

ZS Genetics Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1372771
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Hydrocision IncBiotechnologySeed$9.2M$10.0Mnetwork1 shared operator · same sector · same stage
Calosyn Pharma, Inc.BiotechnologySeed$2.9M$8.4Msame sector · same stage
Bellwether Bio, Inc.BiotechnologySeed$2.9M$7.8Msame sector · same stage
Acworth Pharmaceuticals, Inc.BiotechnologySeed$3.0M$9.9Msame sector · same stage
Origin Life Sciences, Inc.BiotechnologySeed$3.0M$5.8Msame sector · same stage
OrisDx Inc.BiotechnologySeed$2.8M$8.4Msame sector · same stage
Advanced Disinfection Technologies, LLCBiotechnologySeed$3.0M$4.8Msame sector · same stage
Vira Regen Inc.BiotechnologySeed$3.0M$5.6Msame sector · same stage
Frequently asked
How much funding has ZS Genetics Inc raised?
ZS Genetics Inc has raised approximately $2.9M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is ZS Genetics Inc's estimated valuation?
Provath's modeled valuation for ZS Genetics Inc is approximately $7.5M (modeled range $122K–$59.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is ZS Genetics Inc at?
ZS Genetics Inc's latest modeled financing stage is Seed. Its most recent recorded round closed around Mon Apr 27.
What does ZS Genetics Inc do and where is it based?
ZS Genetics Inc operates in the Biotechnology sector, based in Wakefield.
Explore related

See where ZS Genetics Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at ZS Genetics Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.